JNJ · News · 20261102N

Impella Clinical Outcomes

JOHNSON & JOHNSON · 2026-11-02 · Importance 20 · Surprise 24

Johnson & Johnson presented analyses at the Transcatheter Cardiovascular Therapeutics 2026 symposium on Impella-supported high-risk percutaneous coronary intervention (HRPCI). The observational analyses included 1,379 patients across the United States and Europe and reported mortality outcomes numerically below those in the CHIP-BCIS3 study. The findings do not establish a causal link because of the observational designs and differences between studies; the ongoing PROTECT IV randomized trial is expected to provide definitive evidence in 2027.

Key facts

• Johnson & Johnson expects definitive evidence on Impella-supported high-risk coronary procedures from the ongoing PROTECT IV randomized controlled trial in 2027. source
• Johnson & Johnson reported three observational analyses of Impella-supported high-risk percutaneous coronary intervention involving 1,379 patients across the US and Europe; mortality outcomes at different intervals were numerically lower than figures from CHIP-BCIS3. source
• Johnson & Johnson said the observational Impella findings do not establish a causal link because of the observational nature and differences in study designs. source